Project Grant HT94252510909
Award Date 11/1/25
Completion Date 10/31/28
Dollars Obligated $939K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Israel
Similar Awards
- The Defense Health Agency awarded a $1,078,882 Project Grant to the Sanford Burnham Prebys Medical Discovery Institute located in La Jolla, CA. The federal grant, funded through the Military Medical Research and Development program (CFDA 12.420), supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the public. The research project focuses on a "Chemical Engineering Approach to ALS that Amplifies a More Sophisticated View of the...
- The Defense Health Agency awarded a $659,922 Project Grant to Macquarie University in Australia under the Military Medical Research and Development program (CFDA 12.420). The grant funds a gene therapy research project aimed at developing a treatment for delaying the onset of Amyotrophic Lateral Sclerosis (ALS) through nuclear TDP-43 supplementation. The research will be conducted at Macquarie University over a 2-year period from September 2025 to September 2027. This project grant is part of...
- This Project Grant award, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research to develop neuronal exosome-based biomarkers for the diagnosis and disease progression of amyotrophic lateral sclerosis (ALS). The total award amount is $1,181,251.00, with a performance period from April 15, 2025 to April 14, 2028. The principal investigator for this grant is the University of California, Los Angeles (UCLA), which has a...
- The Department of the Army Medical Command awarded a $1,180,437 Project Grant to the University of California, Los Angeles (UCLA) under the Military Medical Research and Development program (CFDA 12.420). The grant supports UCLA's research to evaluate circulating cell-free DNA as a biomarker for diagnosing and tracking the progression of amyotrophic lateral sclerosis (ALS). The award began on March 1, 2024 and is scheduled for completion by February 28, 2026. Through this Project Grant, UCLA...
- This federal Project Grant award of $1,072,079.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports research by the Massachusetts Institute of Technology (MIT) to develop diagnostic biomarkers for clinical subtypes of amyotrophic lateral sclerosis (ALS). The research aims to advance the understanding and treatment of ALS, a neurological disorder, with potential benefits for military service members and the broader public....
- The Department of Defense's Defense Health Agency awarded a $1,035,460 Project Grant to Brigham & Women's Hospital Inc. to conduct research on "TREATMENT OF ALS BY NASAL ADMINISTRATION OF ANTI-CD3 MONOCLONAL ANTIBODY TO MODULATE INFLAMMATORY MICROGLIA AND PREVENT MOTOR NEURON DEGENERATION". This grant, funded under the Military Medical Research and Development program (CFDA 12.420), aims to develop a new treatment approach for amyotrophic lateral sclerosis (ALS) by modulating...
- This Project Grant award of $2,163,115.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by Pathmaker Neurosystems Inc. to develop a noninvasive neuromodulation approach to slow the progression of amyotrophic lateral sclerosis (ALS) by suppressing neuronal hyperexcitability. The research, taking place in Boston, MA, aims to explore this innovative therapeutic method over the 2-year performance period...
- This federal Project Grant award, valued at $1,103,084.00, was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The funding supports the development of a personalized blood-based diagnostic assay for early detection of Amyotrophic Lateral Sclerosis (ALS) at Arizona State University. The university will collaborate with a sub-awardee, Georgetown University, to conduct the research. The project aims to transform healthcare for...
- The Defense Health Agency awarded a $1.19 million Project Grant to The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. from May 1, 2023 to April 30, 2026 under the Military Medical Research and Development program (CFDA 12.420). The grant funds research into targeting excessive sphingolipid synthesis for treatment of amyotrophic lateral sclerosis (ALS) being conducted by Dr. Teresa M. Dunn of the Uniformed Services University of the Health Sciences. Dr. Dunn is...
- The U.S. Defense Health Agency awarded a $952,162 Project Grant to the University of Massachusetts Medical School (UMMS) to support the development of "NOVEL, IMPROVED AAV VECTORS FOR THE TREATMENT OF ALS". The grant is funded through the Military Medical Research and Development program (CFDA 12.420) and has a performance period from August 1, 2025 to July 31, 2027. The project aims to advance biomedical research into novel adeno-associated virus (AAV) vector technologies with the...
The Defense Health Agency awarded a $939,325.00 Project Grant titled "GLOBALS - GLOBAL OMIC BIOMARKER RESEARCH FOR ALS" to the Weizmann Institute of Science in Israel. The grant, which runs from November 1, 2025 to October 31, 2028, is funded under the Military Medical Research and Development program (CFDA 12.420). The award supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. Specifically, the Weizmann Institute will conduct global omic biomarker research for amyotrophic lateral sclerosis (ALS) to develop innovative medical solutions addressing critical health challenges.
Generated 10/21/25, 6:31 AM
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 8/15/25 | ||
| Not listed | $939.3k | 8/12/25 |